2026 NPPES data Medical Biochemical Genetics NPI 1902187859 M.D.
Verify on CMS →

ANNETTE FEIGENBAUM, M.D.

Medical Biochemical Genetics in SAN DIEGO, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
32
Medicare Part D claims · Medical Biochemical Genetics avg: 29
Generic prescribing
3%
generic claims · 97% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$2.3K
6 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

ANNETTE FEIGENBAUM, M.D. filed 32 Medicare Part D claims in 2023 as a Medical Biochemical Genetics in SAN DIEGO, California, prescribing 3% generic.

32
Part D claims, 2023
3%
generic prescribing
$2.3K
industry payments (Sunshine Act)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

ANNETTE FEIGENBAUM, M.D.'s Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

32 0th percentile higher than 0% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). This entry sits in this band. 200–400: 182,923 prescribers (13%). Above this entry. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic — not verified)

ANNETTE FEIGENBAUM, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about ANNETTE FEIGENBAUM, M.D.?

Quality data not reported

NPI registry status

Active

Issued 09/06/2011

NPI 1902187859

Primary specialty

Medical Biochemical Genetics

Rare

21 US NPIs in this specialty

Medicare Part D claims

32 10% vs specialty avg

2023 prescription claims

Specialty avg: 29

Specialty distribution in California

How Medical Biochemical Genetics compares to other specialties among California providers

California providers

Medical Biochemical Genetics share within California

1. Medical Biochemical Genetics42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Medical Biochemical Genetics share within California

Specialty board-certification context

Estimated specialty board-certified rate — Medical Biochemical Genetics (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Medical Biochemical Genetics ABMS/AOA estimate

Est. board-certified rate (Medical Biochemical Genetics) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Medical Biochemical Genetics) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

ANNETTE FEIGENBAUM, M.D. appears in the CMS NPPES registry as a Medical Biochemical Genetics provider holding M.D. credentials at 7920 FROST ST STE 200, SAN DIEGO, CA, 92123, with a listed phone of (858) 576-1700. NPI 1902187859 was issued on 09/06/2011. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what FEIGENBAUM most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 32 prescription claims written by this provider, covering N/A Medicare beneficiaries and totaling roughly $818K in drug spend, split 97% brand-name and 3% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Medical Biochemical Genetics is a narrow specialty nationwide, with 21 enrolled providers across 13 states and an average of 29 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

7920 FROST ST STE 200
SAN DIEGO, CA 92123

Provider Details

NPI 1902187859
Specialty Medical Biochemical Genetics
Credentials M.D.
Gender Female
NPI Issued 09/06/2011

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for ANNETTE FEIGENBAUM, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$2.3K

Largest payer

Amgen Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to ANNETTE FEIGENBAUM, M.D.. To verify ANNETTE FEIGENBAUM, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

ANNETTE FEIGENBAUM, M.D. — brand share 97.0%
Specialty average (est.)

97% brand-name claims vs 3% generic, on 32 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

32
Total Claims
$818K
Total Drug Cost
N/A
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
38
Total Day Supply
1,086
Brand vs Generic
97% brand / 3% generic
Brand Drug Cost
$818K

Patient Demographics

Average Patient Age
61.7 years
Avg HCC Risk Score
1.32

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Galafold
Migalastat Hcl
14
Cerdelga
Eliglustat Tartrate
13

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Medical Biochemical Genetics Overview

How ANNETTE FEIGENBAUM, M.D. fits within the Medical Biochemical Genetics landscape nationally.

21
Medical Biochemical Genetics Providers in US
13
States with Medical Biochemical Genetics
29
Avg Claims per Provider

ANNETTE FEIGENBAUM, M.D.'s 32 claims are above the specialty average of 29.

Nearby Medical Biochemical Genetics Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as FEIGENBAUM.

Compare Medical Biochemical Genetics nationally: see state-by-state distribution →

Frequently Asked Questions

What is ANNETTE FEIGENBAUM, M.D.'s specialty?
ANNETTE FEIGENBAUM, M.D. specializes in Medical Biochemical Genetics and practices in SAN DIEGO, California. Credentials: M.D..
How much does ANNETTE FEIGENBAUM, M.D. prescribe under Medicare Part D?
In 2023, ANNETTE FEIGENBAUM, M.D. wrote 32 Medicare Part D claims totaling $818K in drug costs for N/A beneficiaries.
Where is ANNETTE FEIGENBAUM, M.D. located?
ANNETTE FEIGENBAUM, M.D. is located at 7920 FROST ST STE 200, SAN DIEGO, CA, 92123. Phone: (858) 576-1700.
What is ANNETTE FEIGENBAUM, M.D.'s NPI number?
ANNETTE FEIGENBAUM, M.D.'s National Provider Identifier (NPI) is 1902187859, issued on 09/06/2011.
Does ANNETTE FEIGENBAUM, M.D. prescribe more brand-name or generic drugs?
ANNETTE FEIGENBAUM, M.D.'s prescribing is 97% brand-name and 3% generic drugs by claim count, with $818K in brand drug costs.
How many Medical Biochemical Genetics providers are there in the US?
There are 21 Medical Biochemical Genetics providers across 13 states in the US. The average Medical Biochemical Genetics provider writes 29 Medicare Part D claims per year.
What drugs does ANNETTE FEIGENBAUM, M.D. prescribe most often?
Based on 2023 Medicare Part D data, ANNETTE FEIGENBAUM, M.D.'s most frequently prescribed drugs include Galafold, Cerdelga. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does ANNETTE FEIGENBAUM, M.D. accept Medicare?
ANNETTE FEIGENBAUM, M.D. appears in CMS Medicare data with 32 Part D claims and N/A Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify ANNETTE FEIGENBAUM, M.D.'s credentials?
ANNETTE FEIGENBAUM, M.D.'s NPI is 1902187859 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology